icometrix’s Post

Join our webinar on June 6th at 11:00 am MDT, "Using Proteomics to Advance Understanding of Alzheimer’s Disease," featuring Dr. Erik Johnson, Assistant Professor at Emory University's Department of Neurology.     Discover breakthroughs in Alzheimer's research as Dr. Johnson navigates through dynamic brain changes and biomarker discovery using a proteomic approach.      Explore the potential of affinity-based proteomics in identifying reliable biomarkers and gain insights into intricate networks like proteostasis and the matrisome. Don't miss this opportunity to learn from a leading expert contributing to the fight against Alzheimer's disease.     Register now here: https://lnkd.in/gDbrrwms     #AlzheimersResearch #Proteomics #Webinar 

#ICYMI our team shared interim results on our Phase 2 IGNITE study, findings from ILLUMINATE our Natural History Study in individuals with #ALSP, and details on iluzanebart (VGL101) as a potential immunotherapy for ALSP at the 2024 American Academy of Neurology (AAN) Annual Meeting. Learn more about our multiple presentations: bit.ly/3UmlRUR . #AAN2024 #HarnessingMicroglia

#BrainAwarenessWeek is the global campaign to foster public enthusiasm and support for brain science. The Global Use of Medicines 2024 report shares a few exciting developments in the area of brain science: 🧠The last five years have brought a new wave of rare disease neurological treatments. 🧠Dozens of these treatments with orphan designations were approved. 🧠Other diseases with larger populations such as migraine, depression and anxiety have also seen a range of new treatments approved and launched. 🧠The fundamentals of CNS innovation are changing thanks to scientific advances in genomics, biomarkers, diagnostics, and imaging techniques and/or regenerative medicine, combined with disruptive digital technologies. Page 50 of The Global Use of Medicines 2024 report shares the drivers of spending growth in neurology. Download the report here: https://bit.ly/3VjnPq2

Adriana González-Caballero joined her Kx Advisors and BGB Group colleagues reporting on findings from the annual Alzheimer's Association International Conference in Philly as one of our distinguished neurology experts. In partnership with Chris Waybill, Chloe Weiser, and BGB Group colleagues Juan M. Valdez Capuccino, Ph.D. and Exene Anderson, PhD, Adriana is digging a bit deeper into one of the topics that came up - diagnostic hurdles and blood biomarkers in Alzheimer's Disease diagnosis. Did you know the average predicted wait time between clinical diagnosis and treatment of AD is 18.6 months? We invite you to learn more about the different types of BBMs and how they may evolve patient diagnosis of AD and the treatment journey. Read more about this topic in the link below: https://go.bgbx.ai/BBBM

On this World Alzheimer’s Day, WuXi AppTec joins in bringing attention to the global health crisis of this debilitating disease. We support drug discovery teams in the search for new therapies to prevent, treat and cure Alzheimer’s and other neurodegenerative diseases via our integrated services platform which includes a comprehensive panel of advanced technologies and validated disease models. Click this link to learn more about our neurobiology services platform, including a case study highlighting the application of a clinical biomarker in a mouse model for Alzheimer’s: https://lnkd.in/evwkRskZ #DrugDiscovery #KnowDementia, #KnowAlzheimers #WorldAlzheimers #Alzheimer’s

#BrainAwarenessWeek is the global campaign to foster public enthusiasm and support for brain science. The Global Use of Medicines 2024 report shares a few exciting developments in the area of brain science: 🧠The last five years have brought a new wave of rare disease neurological treatments. 🧠Dozens of these treatments with orphan designations were approved. 🧠Other diseases with larger populations such as migraine, depression and anxiety have also seen a range of new treatments approved and launched. 🧠The fundamentals of CNS innovation are changing thanks to scientific advances in genomics, biomarkers, diagnostics, and imaging techniques and/or regenerative medicine, combined with disruptive digital technologies. Page 50 of The Global Use of Medicines 2024 report shares the drivers of spending growth in neurology. Download the report here: https://bit.ly/4cg1cIY #IQVIAMIDAS #MarketPrognosis #ForecastLink

Last week, here on LinkedIn, you met Juan M. Valdez Capuccino, Ph.D. as he walked the halls of the annual Alzheimer's Association International Conference in Philly as one of BGB Group's distinguished neurology experts. Today, in partnership with Exene Anderson, PhD and our Kx Advisors colleagues Chris Waybill, Adriana González-Caballero, and Chloe Weiser, Juan is digging a bit deeper into one of the topics that came up - blood biomarkers in Alzheimer's Disease diagnosis. Did you know the average predicted wait time between clinical diagnosis and treatment of AD is 18.6 months? We invite you to learn more about the different types of BBMs and how they may evolve patient diagnosis of AD and the treatment journey. Read more about this topic in the link below: https://go.bgbx.ai/BBBM

Excited to share that our 15th paper of 2024 is out now in BMC Neurology! 📰 Key Findings: Safety: The Sinopharm vaccine was well tolerated among people with multiple sclerosis (MS), with minimal serious adverse events. Efficacy: Promising protection against COVID-19, though breakthrough cases were noted. Immunogenicity: Suboptimal antibody response in MS patients on Fingolimod and anti-CD20 therapies, highlighting a need for further research. Check out the full study here: https://lnkd.in/gFJ7g8P8 📖 Also, I want to thank Melika Jameie for the opportunity she gave me to analyze the data. Authors: Melika Jameie, Zahra Ebadi, Mobina Amanollahi, Kiana Amani, Fatemeh Nobahari, Alireza Abdollahi, Marzieh Sadat Mousavi, Bahareh Pourghaz & Mohammad Hossein Harirchian  #Research #MultipleSclerosis #COVID19 #VaccineResearch #Sinopharm #Neurology

#Parkinson #brainimaging #singlenucleotide #cognition Impact of cognition-related single nucleotide polymorphisms on brain imaging phenotype in Parkinson’s disease https://lnkd.in/g7uHN6Xk Multiple single nucleotide polymorphisms may contribute to cognitive decline in Parkinson’s disease. However, the mechanism by which these single nucleotide polymorphisms modify brain imaging phenotype remains unclear. The aim of this study was to investigate the potential effects of multiple single nucleotide polymorphisms on brain imaging phenotype in Parkinson’s disease. This study provides evidence of an association between genetic factors, cognitive functions, and multi-modality neuroimaging biomarkers in Parkinson’s disease.

A paper published in Nature Reviews Neurology, discusses suspected non-AD pathophysiology (SNAP), which is common in individuals with MCI and normal cognition (NC). People with NC-SNAP have a low risk of cognitive decline over 7 years, and longer follow-up studies are needed to demonstrate whether they will eventually show faster cognitive decline than those with NC and normal biomarkers. People with MCI-SNAP have an increased risk of developing clinical AD dementia at follow-up (annual conversion rate 7% compared with 1% for MCI with normal biomarkers). This finding suggests that SNAP might partly reflect a lack of sensitivity of biomarkers to detect early amyloid pathology, although misdiagnosis at follow-up is another possibility. The frequency of AD genetic risk factors in A− T+ individuals with SNAP is similar to that in control individuals and lower than in those with AD. This finding is mainly driven by a lower frequency of APOE ε4 in SNAP than in AD. CSF proteomics have shown that people with SNAP have increased CSF levels of Aβ38 and Aβ40 compared with patients with AD and control individuals, possibly reflecting the effects of tau pathology without marked amyloid aggregation. A distinguishing feature in people with MCI-SNAP is a decrease in CSF levels of proteins that are highly expressed in the choroid plexus, suggesting a role for this structure in MCI-SNAP. Neuropathological studies have indicated a range of possible neuropathologies associated with SNAP, including TDP43-related pathologies (LATE and FTLD-TDP), tau pathology (PART, AGD and PSP), LBD and cerebrovascular pathology. In older individuals, SNAP probably represents a combination of neuropathological lesions. Nature Portfolio Springer Nature Group #neuroscience #neurology #neurologicaldisorders #neurodegenerativedisorders #alzheimersdisease #alzheimer #cognitivedecline #dementia #biomarkers #precisionmedicine #diagnosis #earlydiagnosis #earlydetection #prediction #SNAP #PART #FTD #ALS #Parkinsonsdisease #AGD #PSP #LATE #neuropathology #brain #brainresearch #clinicalresearch #MCI #cognition #amyloid #pathophysiology #riskfactors #classification #differentialdiagnosis